Comparison · NCT04649151-b1799155
Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition). Trial comparisons, record NCT04649151-b1799155. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04649151-b1799155
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.000934 | 0.000256 | 0.0034 | wilson | |
| Risk in group 2 | 0.00862 | 0.00454 | 0.0163 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00769 | -0.0154 | -0.00292 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.108 | 0.0234 | 0.5 | log | |
| Odds ratio, group 1 over group 2 | 0.107 | 0.0232 | 0.498 | log | |
| Number needed to treat, for one fewer participant with the outcome on Part 1A: mRNA-1273 100 μg than on Part 1A: Placebo | 130 | 64.9 | 342 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 1A: mRNA-1273 100 μg | Participants received at least 1 of 2 doses of 100 μg mRNA-1273 by IM injection (Day 1 and Day 29). | 2 | 2,142 | OG000 |
| Group 2 | Part 1A: Placebo | Participants received at least 1 of 2 doses of placebo matched to mRNA-1273 100 μg by IM injection (Day 1 and Day 29). | 9 | 1,044 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)
- Description
Secondary case definition of COVID-19 was defined by the following criteria: 1 systemic or respiratory symptoms: fever (temperature \> 38ºC/≥ 100.4ºF), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea, and at least one positive test for SARS-CoV-2.
- Time frame
- Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
- Population
Part 1A PP Set for Efficacy: all randomized participants who received planned doses of study drug, had no immunologic or virologic evidence of prior COVID-19, and had no major protocol deviations that impact key or critical efficacy data.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
- NCT number
- NCT04649151
- Phases
- PHASE2, PHASE3
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo, mRNA-1273.222
- Lead sponsor
- ModernaTX, Inc.
- Results first posted
- 2025-09-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04649151?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04649151-b1799155